Lp-PLA2 is widely concerned in recent years as a vascular inflammation factor that plays an important role in the development of atherosclerosis .The level of plasma Lp-PLA2 is related to the stability of carotid artery atherosclerotic plaque .it is an independent predictor of coronary heart disease risk . Its specific inhibitor Darapladib also becomes a hotspot of clinical cardiovascular pharmaceutical research . However,two randomized, placebo-controlled, double-blind, international, multicenter, event-driven trials, STABILITY and SOLID-TIMI 52, have shown that Darapladib could not significantly reduce the risk of cardiovascular events.